SNOA

Sonoma Pharmaceuticals, Inc.
1 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

The bull case has evolved from a simple product-launch story into a broader platform play.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The bear case has intensified as the company's financial instability becomes more apparent.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SNOA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Sonoma Pharmaceuticals is attempting to transition from a niche biotech entity into a scalable consumer health platform.…

Latest Available Quarter (Q2 '26 (10-K))

Core Takeaway

Not specified.

Investor Lens

The trade-off is between a disruptive product platform and a distressed financial structure.

Watch Next

FDA reclassification of HOCl products and the 2027 profitability milestone.

Calculated Financial Trajectory (Click to filter signals)

Revenue (M)Not Disclosed
FY '26: Not Disclosed
Net Income (M)Not Disclosed
FY '26: Not Disclosed
Gross Margin (%)Not Disclosed
FY '26: Not Disclosed
Net Debt (M)10.0
FY '26: 10.0

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.03Q2 '26 (10-K)

Signal Timeline

bullishJun 16

Shift toward high-margin direct-to-consumer and professional channels.

margin expansion
70%
bearishJun 16

FDA proposed reclassification of HOCl products to Class II devices.

regulatory action
60%
neutralJun 16

Extension of intercompany loans to Mexican subsidiary to 2032.

debt restructure
50%

Filing History

10-KJun 16, 2026
Expand Sequence

The 10-K filing reveals a company at a critical crossroads, balancing a promising product pipeline against a strained financial foundation. While the operational wins in retail distribution and regulatory clearances provide a roadmap for growth, the underlying fiscal health is marred by material weaknesses in internal controls and a heavy reliance on related-party financing to sustain operations. Investors are left to weigh the potential of a high-margin, first-mover advantage in the HOCl space against the immediate risks of a liquidity crunch. The outcome will likely depend on whether the company can successfully execute its 2027 profitability plan without requiring further dilutive capital raises or facing a catastrophic regulatory setback in its primary manufacturing hub in Mexico.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.